These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
364 related articles for article (PubMed ID: 10416590)
1. Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration. Eggert AA; Schreurs MW; Boerman OC; Oyen WJ; de Boer AJ; Punt CJ; Figdor CG; Adema GJ Cancer Res; 1999 Jul; 59(14):3340-5. PubMed ID: 10416590 [TBL] [Abstract][Full Text] [Related]
3. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines. Wang J; Saffold S; Cao X; Krauss J; Chen W J Immunol; 1998 Nov; 161(10):5516-24. PubMed ID: 9820528 [TBL] [Abstract][Full Text] [Related]
4. Administration route-dependent vaccine efficiency of murine dendritic cells pulsed with antigens. Okada N; Tsujino M; Hagiwara Y; Tada A; Tamura Y; Mori K; Saito T; Nakagawa S; Mayumi T; Fujita T; Yamamoto A Br J Cancer; 2001 Jun; 84(11):1564-70. PubMed ID: 11384109 [TBL] [Abstract][Full Text] [Related]
5. [Ad hTRP2 - mediated immunity against melanoma is enhanced by dendritic cells pulsed with peptide]. Tan XH; Liu C; Wan YH Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):658-61. PubMed ID: 17274369 [TBL] [Abstract][Full Text] [Related]
6. Dendritic cells break tolerance and induce protective immunity against a melanocyte differentiation antigen in an autologous melanoma model. Schreurs MW; Eggert AA; de Boer AJ; Vissers JL; van Hall T; Offringa R; Figdor CG; Adema GJ Cancer Res; 2000 Dec; 60(24):6995-7001. PubMed ID: 11156402 [TBL] [Abstract][Full Text] [Related]
8. Comparison of recombinant adenovirus and synthetic peptide for DC-based melanoma vaccination. Steitz J; Tormo D; Schweichel D; Tüting T Cancer Gene Ther; 2006 Mar; 13(3):318-25. PubMed ID: 16151477 [TBL] [Abstract][Full Text] [Related]
9. Combination vaccine of dendritic cells (DCs) and T cells effectively suppressed preestablished malignant melanoma in mice. Asada H; Kishida T; Hirai H; Shin-Ya M; Imanishi J; Takeuchi M; Mazda O Cancer Lett; 2006 Aug; 240(1):83-93. PubMed ID: 16246489 [TBL] [Abstract][Full Text] [Related]
10. Dendritic cells transduced with TAT protein transduction domain-containing tyrosinase-related protein 2 vaccinate against murine melanoma. Shibagaki N; Udey MC Eur J Immunol; 2003 Apr; 33(4):850-60. PubMed ID: 12672050 [TBL] [Abstract][Full Text] [Related]
11. Targeting dendritic cells with antigen-containing liposomes: a highly effective procedure for induction of antitumor immunity and for tumor immunotherapy. van Broekhoven CL; Parish CR; Demangel C; Britton WJ; Altin JG Cancer Res; 2004 Jun; 64(12):4357-65. PubMed ID: 15205352 [TBL] [Abstract][Full Text] [Related]
12. Dendritic cells, loaded with recombinant bacteria expressing tumor antigens, induce a protective tumor-specific response. Rescigno M; Valzasina B; Bonasio R; Urbano M; Ricciardi-Castagnoli P Clin Cancer Res; 2001 Mar; 7(3 Suppl):865s-870s. PubMed ID: 11300484 [TBL] [Abstract][Full Text] [Related]
13. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies. Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962 [TBL] [Abstract][Full Text] [Related]
14. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen. Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645 [TBL] [Abstract][Full Text] [Related]
15. [Enhanced antitumor effects induced by lymphotactin gene-modified dendritic cells after pulsed with tumor antigen peptide]. Zhang W; He L; Cao X Zhonghua Yi Xue Za Zhi; 1999 Mar; 79(3):170-3. PubMed ID: 11601032 [TBL] [Abstract][Full Text] [Related]
16. Adoptive transfer of immature dendritic cells with autologous or allogeneic tumor cells generates systemic antitumor immunity. Melcher A; Todryk S; Bateman A; Chong H; Lemoine NR; Vile RG Cancer Res; 1999 Jun; 59(12):2802-5. PubMed ID: 10383135 [TBL] [Abstract][Full Text] [Related]
17. Dendritic cells pulsed or fused with AML cellular antigen provide comparable in vivo antitumor protective responses. Weigel BJ; Panoskaltsis-Mortari A; Diers M; Garcia M; Lees C; Krieg AM; Chen W; Blazar BR Exp Hematol; 2006 Oct; 34(10):1403-12. PubMed ID: 16982333 [TBL] [Abstract][Full Text] [Related]
18. Cytotoxic T lymphocytes responding to low dose TRP2 antigen are induced against B16 melanoma by liposome-encapsulated TRP2 peptide and CpG DNA adjuvant. Jérôme V; Graser A; Müller R; Kontermann RE; Konur A J Immunother; 2006; 29(3):294-305. PubMed ID: 16699372 [TBL] [Abstract][Full Text] [Related]
19. Enhancement of immunity by a DNA melanoma vaccine against TRP2 with CCL21 as an adjuvant. Yamano T; Kaneda Y; Huang S; Hiramatsu SH; Hoon DS Mol Ther; 2006 Jan; 13(1):194-202. PubMed ID: 16112911 [TBL] [Abstract][Full Text] [Related]